BioMarin Pharmaceuticals BMRN Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's short-term investments?
- BioMarin Pharmaceuticals (BMRN) reported short-term investments of $0 in Q1 2026.
- How has BioMarin Pharmaceuticals's short-term investments changed year-over-year?
- BioMarin Pharmaceuticals's short-term investments decreased by 100.0% year-over-year, from $223.53M to $0.
- What is the long-term trend for BioMarin Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's short-term investments has grown at a -9.8% compound annual growth rate (CAGR), from $416.23M to $248.93M.
- What does short-term investments mean?
- Financial investments that the company expects to turn into cash within one year.
- How do you interpret short-term investments?
- An increase indicates the company is successfully deploying excess cash into interest-bearing instruments, while a decrease may signal cash usage for operations or acquisitions.
- How does short-term investments compare across companies?
- Commonly used by profitable or well-capitalized pharmaceutical companies to manage working capital cycles.